<DOC>
	<DOCNO>NCT01488097</DOCNO>
	<brief_summary>This extension study first clinical study SBC-102 ( sebelipase alfa ) treatment LAL Deficiency . It open label study adult patient liver dysfunction due Lysosomal Acid Lipase ( LAL ) Deficiency . This study assess long-term safety , tolerability , efficacy SBC-102 . The targeted number study 9 evaluable subject .</brief_summary>
	<brief_title>Extension Study Evaluate Long-Term Safety , Tolerability , Efficacy SBC-102 ( Sebelipase Alfa ) Adult Subjects With Lysosomal Acid Lipase Deficiency</brief_title>
	<detailed_description>Cholesteryl Ester Storage Disease ( CESD ) late onset phenotype Lysosomal Acid Lipase ( LAL ) Deficiency , Lysosomal Storage Disorder , also early onset phenotype know Wolman Disease primarily affect infant . CESD present childhood often go unrecognized adulthood underlie pathology advance . Many sign symptom common patient liver condition . CESD autosomal recessive genetic condition characterize hepatomegaly , persistently abnormal liver function test ( LFTs ) type II hyperlipidemia . Splenomegaly evidence mild hypersplenism may affect patient . Untreated , CESD may lead fibrosis , cirrhosis , liver failure death .</detailed_description>
	<mesh_term>Wolman Disease</mesh_term>
	<mesh_term>Cholesterol Ester Storage Disease</mesh_term>
	<criteria>Subject receive 4 schedule dos SBC102 study LALCL01 lifethreatening unmanageable study drug toxicity . Clinically significant concurrent disease , serious intercurrent illness , concomitant medication extenuate circumstance Clinically significant abnormal value laboratory screening test , liver function lipid panel test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Enzyme Replacement Therapy ( ERT )</keyword>
	<keyword>Lysosomal Storage Disease</keyword>
	<keyword>Late Onset Lysosomal Acid Lipase ( LAL ) Deficiency</keyword>
	<keyword>Acid cholesteryl ester hydrolase deficiency , type 2</keyword>
	<keyword>Acid lipase disease</keyword>
	<keyword>Cholesterol ester hydrolase deficiency</keyword>
	<keyword>LAL Deficiency</keyword>
	<keyword>LIPA Deficiency</keyword>
	<keyword>Wolman disease</keyword>
</DOC>